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physiotherapy over a 3-week period was safe and signifi-
cantly improved mood status in ischemic stroke patients. 
 Future studies are needed which determine the optimal 
therapeutic window for and dosage of psychostimulants as 
well as identify those stroke patients who might benefit the 
most from treatment.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 The physical and psychological sequelae caused by 
stroke can be devastating  [1] . Post-stroke depression 
(PSD) is the most common neuropsychiatric consequence 
of stroke  [2] and affects 6–79% of stroke survivors  [3] . 
Early recognition and effective treatment of PSD leads
to more favorable functional and psychosocial outcomes 
and reduces disease burden as well as morbidity and mor-
tality  [4] . In a recent systematic review, Hackett et al.  [5] 
reported that antidepressants could reduce mood disor-
der symptoms among PSD patients but had no clear ef-
fect on prevention or remission of depressive illness af-
ter stroke. As deficits in central catecholamine levels are 
thought to play a major role in the etiology of PSD, en-
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 Abstract 
 Background/Aim: Stimulant medications can enhance 
mood and cognition in stroke rehabilitation, but human clin-
ical trial results are inconclusive. We sought to prospectively 
study the effects of levodopa (LD) and/or methylphenidate 
(MPH) in combination with physiotherapy on mood and cog-
nition following stroke in human subjects.  Methods: Isch-
emic stroke patients were enrolled in our study 15 to 180 
days after stroke onset. The patients were randomized into 
four medication groups (MPH, LD, MPH + LD, or placebo) and 
received a 15-day course of medication therapy (1 dose daily) 
and 45-min standard physiotherapy treatment daily. Mood 
and cognitive function were assessed at the study onset
and 15, 90 and 180 days after study enrollment.  Results: The 
strongest improvement of mood and cognition was found 
between baseline and the first follow-up immediately after 
the intervention. A significant improvement in mood was 
also found in the combined treatment group (MPH + LD) at 
90 and 180 days, compared to the placebo group.  Conclu-
sions: A 15-day course of daily MPH + LD combined with 
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hancement of central catecholaminergic levels via stimu-
lant use has been proposed to be a therapeutic strategy for 
PSD  [6] . Having catecholamine-stimulating properties, 
methylphenidate (MPH) and levodopa (LD) are both ide-
al pharmacologic agents to treat PSD due to cost consid-
erations, favorable pharmacodynamics/pharmacokinet-
ics, and side effect profiles relative to other stimulant 
medications  [7–10] . Preliminary studies of stimulant 
medication use during stroke rehabilitation and PSD 
have been favorable  [11] , but randomized clinical trials in 
subacute and chronic phases are still needed to identify 
optimal pharmacotherapies. Accordingly, the aim of this 
study was to determine if LD and/or MPH in combina-
tion with physiotherapy could improve mood and cogni-
tion in stroke patients.
 Methods 
 Patient Selection Criteria 
 Patients from 8 acute care hospitals located in Tehran and 
Qom, Iran, who presented and were diagnosed with ischemic 
chronic stroke and limb (arm or leg) paresis between March 2006 
to September 2008, were enrolled. The enrollment window ranged 
from 15 to 180 days after stroke onset to permit acute manage-
ment of stroke. Consenting patients were subsequently admitted 
for outpatient rehabilitation treatment at the Neurorehabilitation 
Clinic of Rofeydeh Hospital affiliated to the University of Social 
Welfare and Rehabilitation, Tehran, Iran. Demographic data col-
lected from research participants included gender, age, estab-
lished cerebrovascular risk factors, dominant paretic side, time of 
stroke onset, and history of previous stroke.
 Patients were excluded if (a) they were unable to respond or 
directly consent; (b) they had comorbidities requiring strict blood 
pressure control and would be put at risk by the potential of hy-
pertension from MPH therapy (history of hemorrhagic stroke, 
recent myocardial infarction within a 4-week period, decompen-
sated cardiac insufficiency, tachycardia, uncontrolled hyperten-
sion, unstable metabolic disease, and glaucoma); (c) they may suf-
fer adverse outcomes from the stimulant effects of MPH, includ-
ing seizure and agitation; (d) they had major cognitive deficits 
that would prevent adequate study participation; (e) they are cur-
rently taking alpha-adrenergic agonists, antagonists, neurolep-
tics, benzodiazepines, MAO inhibitors, or anti-depressants, and 
(f) if they had a known hypersensitivity to MPH or LD.
 The study was approved by the Ministry of Health in Iran and 
the Ethics Committee of University of Social Welfare and Reha-
bilitation. All patients provided written informed consent.
 Randomization 
 Consenting patients were randomized into a double-blind, 
placebo-controlled trial with a 2  ! 2 factorial design using a com-
puterized randomization program. Initial randomization was 
performed by individuals unrelated to the study. Patients were 
divided into four groups, i.e. MPH, LD, MPH + LD, and place-
bo (P).
 Physiotherapy 
 Patients received a daily 45-min session of standard physio-
therapy treatment with a goal-oriented approach focusing on 
 mobilization using selective movements (coordination exercises, 
strengthening exercises and active relaxation), lying, sitting and 
standing, balance using sensory and visual perceptual training 
and cognition, transfers, and ambulatory activities incorporating 
personal activities of daily living (ADL) and domestic ADL  [12] . 
Movements were practiced with progressively more complex func-
tional activities designed to promote the return of selective muscle 
control of the trunk and limbs  [13] . All therapists provided the 
 patients with a standardized rehabilitation program. The training 
content, but not duration, varied for each patient, depending on 
the severity of his or her paresis. Individuals also received addi-
tional rehabilitation such as speech therapy treatment, depending 
on their neurological impairments. The patients were monitored 
during all sessions to ensure that they received standard rehabili-
tation and that evaluations were performed adequately.
 Pharmacotherapy 
 The drugs, i.e. MPH and/or LD and P, were randomly distrib-
uted in opaque boxes labeled 1–100. The drug protocol developed 
for this study was based on what was prescribed and suggested in 
previous studies  [14] (MPH at a mean dose of 17 mg per day in PSD). 
In this four-group intervention model, drug treatment was given 
in the form of identical white tablets of 2  ! 10 mg of either MPH 
or P and a tablet with either 125 mg LD or P. These tablets were 
administered at least 1 h before the training session to coincide 
with the timing of the peak pharmacological action of the drugs 
 [15, 16] . Treatments were continued for 5 days per week for a total 
of 15 drug therapy sessions. Blood pressure and heart rate were 
monitored for 2 h before and after medication administration. In 
addition, patients were observed for known side effects of LD (car-
diovascular symptoms, nausea, vomiting, and psychosis) and MPH 
(insomnia, nausea, or nervousness) during their rehabilitation.
 Outcome Measures 
 Mood was assessed by the Geriatric Depression Scale (GDS) 
using the methods described by Johnson et al.  [17] and Agrell and 
Dehlin  [18] . The GDS measures changes in the affective rather 
than somatic components of depression and mood using a 15-
item questionnaire. Depression was defined as a GDS of 7.8 or less, 
based upon previous ROC curve analysis (a sensitivity of 0.9 and 
a specificity of 0.84)  [19] . Cognitive function was assessed by 
means of the Mini-Mental State Examination (MMSE)  [20] , an 
exam consisting of 19 questions scored 0 to 30 that addresses five 
areas of cognitive function: orientation to place and time, regis-
tration, attention and calculation, recall, and language. For the 
purposes of our study, we defined cognitive impairment as an 
MMSE score of 21 or lower. Previous efforts by Foroughan et al. 
 [21] have shown this score to have an optimal balance with a sen-
sitivity of 0.9 and a specificity of 0.84.
 Statistical Analysis 
 Descriptive statistics calculated for continuous numeric data 
were means, standard deviations, frequencies, and percentages. 
Cognitive and depression scores were dichotomized to cognitive 
normality (MMSE  1 21) versus cognitive impairment (MMSE 
 ^  21) and to non-depression (GDS  ! 8) versus depression (GDS 
 6 8). The non-parametric one-sample Kolmogorov-Smirnov test 
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was used to identify the normality of variables, and logistic re-
gression was used to calculate odds ratios relating age, gender, 
days since stroke onset, earlier history of stroke, paretic side, and 
risk factors. For each assessment time point (baseline, 15, 90 and 
180 days), the MMSE and GDS scores were collected from each of 
the four treatment groups (MPH, LD, MPH + LD, and P) and were 
compared using ANOVA or Kruskal-Wallis test, based upon data 
normality. A repeated-measures ANOVA was used to identify im-
provements in MMSE and GDS scores with time among the four 
treatment groups and to identify differences in efficacy between 
the treatment groups at each time point. 
 Results 
 Among 1,043 stroke patients initially screened in Qom 
and Tehran, a total of 100 ischemic stroke patients met all 
inclusion criteria and consented for further study. 632 pa-
tients failed to meet the inclusion criteria due to excessive 
duration between stroke onset date and discharge from 
the acute care hospital. Of the 100 patients who partici-
pated in our study, 22 were lost to follow-up either due to 
death (n = 15; 4.2%) or participation failure (n = 7; 11.5%). 
The causes of death were related to the initial stroke and 
not found to be a result of the study intervention. The 22 
patients lost to follow-up were not significantly different 
from the 78 individuals completing the study with re-
spect to age, gender, or delay from stroke onset to treat-
ment. Among the four randomized groups, no significant 
differences were observed concerning demographic (age 
and gender) or clinical characteristics (days since stroke 
onset, prior stroke, hyperlipidemia, heart disease, smok-
ing, and paretic side of stroke;  table 1 ). However, the in-
cidence of diabetes mellitus was significantly different 
between the groups (p = 0.021). No negative side effects 
were observed in any group.
 Outcome of Mood and Cognitive Function 
 Table 2 shows the scores and outcomes at baseline and 
at the three follow-up assessments of cognitive function. 
Baseline data of cognitive function (MMSE) and depres-
sion (GDS) were homogeneous and well balanced in all 
four groups.
 No significant differences in the MMSE score were 
 observed between the groups in general or with repeated 
measures. A post hoc t test revealed that the groups did not 
show any difference at any time of assessment concerning 
MMSE score (p  1 0.1). Cognitive status, as measured by 
the MMSE, improved in all four treatment groups as time 
progressed (F3, 74 = 156.914, p = 0.000). Improvements 
were most substantial between baseline measures and the 
first follow-up at 15 days ( table 2 ). When the patients were 
grouped based upon the presence of depression (GDS  ! 8 
and GDS  6 8, respectively), we found depressed patients 
to have significantly greater improvement in MMSE scores 
than patients who were not depressed.
 Mood status, as measured by GDS, improved signifi-
cantly and continuously in all four groups between base-
line and the three follow-up assessments (F3, 74 = 32.927, 
Table 1.  Demographic characteristics for the four groups
All MPH LD MPH + LD Placebo p value
Mean age 8 SD, years 6489.8 64.05810.8 66.389.5 60.289.1 65.389.6 0.230
Gender, n
Men
Women 
48
30
9
10
14
6
11
8
14
6
0.403
Mean time since stroke 8 SD, days 65.6834.2 66.26840.7 67.8832.1 73.6841.5 54.9818.1 0.386
Prior stroke, n
Yes
No
6 (7.7)
72 (92.3)
3 (15.8)
16 (84.2)
2 (10)
18 (90)
0
19 (100)
1 (5)
19 (95)
0.297
Risk factors, n
HTN
DM
HLP
HD
Smoking
57 (73.1)
44 (65.4)
39 (50.0)
22 (28.2)
18 (23.1)
18 (31.6)
9 (20.4)
12 (30.8)
3 (13.6)
5 (27.8)
15 (26.3)
14 (31.8)
8 (20.5)
7 (31.8)
5 (27.8)
11 (19.3)
6 (13.6)
10 (25.6)
6 (27.3)
4 (22.2)
13 (22.8)
15 (34.1)
9 (23.1)
6 (27.3)
4 (22.2)
0.059
0.021
0.500
0.564
0.959
Paretic side (right/left), n 45/33 (57.7/42.3) 10/9 (52.6/47.4) 13/7 (65/35) 11/8 (57.9/42.1) 11/9 (55/45) 0.874
F igures in parentheses indicate percentages. HTN = Hypertension; DM = diabetes mellitus; HLP = hyperlipidemia; HD = heart 
disease.
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p  ! 0.0001;  table 3 ). As in cognitive function, the most 
substantial improvements were observed between base-
line and the first time point at 15 days ( table  3 ). GDS 
scores improved significantly between baseline and 15-
day assessments (p  ! 0.05), 15-day and 90-day assess-
ments (p  ! 0.05), as well as between 90-day and 180-day 
assessments (p  ! 0.05;  table 3 ). GDS scores differed sig-
nificantly between the groups when performing two-way 
(group x time of assessment) ANOVA. A post hoc t test 
showed that the combined treatment (MPH + LD) dif-
fered significantly from the placebo treatment at 90 days 
(p = 0.018) and 180 days (p = 0.006;  table 3 ).
 Discussion 
 This study revealed that a 3-week regimen of physio-
therapy and daily MPH and/or LD therapy significantly 
improved mood without eliciting major side effects or ad-
versely affecting cognition in ischemic stroke patients. 
These findings suggest that dopaminergic neuromodula-
tion combined with physical activity may enhance mood 
in ischemic stroke survivors.
 The results of this study are consistent with those re-
ported by Lazarus et al.  [22] who demonstrated that over 
half of their study population (n = 53) experienced re-
mission of depressive symptoms. In addition, they also 
demonstrated that response to MPH therapy was sig-
nificantly faster than response to nortriptyline therapy 
(2.4 vs. 27 days). This is consistent with the clinical ex-
perience where traditional antidepressant therapy of-
ten fails due to intolerance in up to one third of patients 
 [23] or delayed onset of action  [24] . The prevalence of 
depression in our study population is in line with that 
reported in other studies where in females, depression 
ranged from 5.9 to 78.3%  [25] and in males from 4.7% 
 [26] to 65.2%  [27] . We had a significantly higher preva-
lence of depression in females than in males at baseline, 
Table 2.  MMSE scores at baseline and at the three follow-up assessments for the four groups
Baseline 15 days 90 days 180 days
Cognitive impairment
Mean of MMSE 8 SD
n (%)
17.983.43
36 (46.1)
16.8783.7
15 (19.2)
17.3183.3
13 (16.7)
17.4783.5
13 (16.6)
Cognitive normality
Mean of MMSE 8 SD
n (%)
25.482.36
42 (53.8)
25.782.27
63 (80.7)
26.582.33
65 (83.3)
26.782.36
65 (83.3)
MPH 21.183 23.782.9 24.783.2 24.983.3
LD 2285.2 24.484.9 25.384.8 25.385
MPH + LD 23.584 25.183.7 2683.2 26.383.4
Placebo 21.186.1 22.885.4 23.885.3 24.285.2
Group effect
F
p
3.231
0.357a
1.008
0.394b
2.540
0.468a
0.859
0.466b
Time effect
F
p
156.914
0.000
Group ! time effect
F
p
0.537
0.659
Post hoc comparison
p n.s. n.s. n.s. n.s.
Post hoc comparison of time points, t value
p 9.07c
11.609d
12.459e
0.000
0.000
0.000
6.668f
8.225g
2.377h
0.000
0.000
0.000
F igures are means 8 SD, unless otherwise indicated. Higher scores of MMSE indicate better function. n.s. = Not significant.
a p value of 2 test. b p value of F test. c Baseline vs. 15-day follow-up. d Baseline vs. 90-day follow-up. e Baseline vs. 180-day follow-
up. f 15-day vs. 90-day follow-up. g 15-day vs. 180-day follow-up. h 90-day vs. 180-day follow-up.
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but gender did not have a significant impact on outcome 
variables.
 Rapid response time is a positive feature of MPH and 
LD when treating dysthymic stroke patients since they 
are often weakly motivated and poorly responsive to re-
habilitation. Moreover, Grade et al.  [11] found that stroke 
patients receiving 5–30 mg MPH daily for 3 weeks showed 
improvements in mood, although no differences between 
the MPH and placebo groups regarding cognitive func-
tion assessed by the MMSE could be observed. However, 
when we divided the patients into two groups based on 
whether or not they were depressed, we found that treat-
ed depressed patients showed a significantly greater im-
provement in MMSE scores than non-depressed patients. 
It seems that patients with stroke had partially reversible 
cognitive dysfunction when their depressive disorder was 
successfully treated  [28] .
 Our finding that mood recovery is improved by a com-
bined treatment (MPH + LD) accords with the result of a 
previous investigation in which there was a significant 
difference in the Barthel Index compared to placebo  [29] . 
It seems that combination therapy may have a widespread 
effect on ADL and mood recovery by the presence of
 L -dopa, thereby causing increased dopamine levels. We 
found that patients with PSD had significantly less recov-
ery in their ADL functions than the post-stroke non-de-
pressed patients. The results of this study are consistent 
with those reported by Chemerinski et al.  [30] , who 
showed that in patients who recovered from PSD, a sig-
nificantly greater improvement in ADL could be ob-
served than in stroke patients whose depression did not 
remit. The mean or average daily dosage of MPH in oth-
er published trials varied between 8 and 30 mg  [11, 31–33] . 
MPH and LD are mild psychostimulants structurally re-
lated to amphetamine and have similar qualities  [34] . Ef-
fects peak 2 h after a single dose of MPH and LD and 
persist for 3–6 h  [16, 35] . The ease of administration, the 
speed of response and the relatively few side effects could 
Table 3.  GDS scores at baseline and at the three follow-up assessments for the four groups
Baseline 15 days 90 days 180 days
Depressed
Mean of GDS 8 SD
n (%)
9.9181.46
33 (42.3)
8.6281.06
8 (10.3)
8.4280.79
7 (8.9)
8.5780.53
7 (8.9)
Non-depressed
Mean of GDS 8 SD
n (%)
4.482
45 (57.7)
4.6781.4
70 (89.7)
4.3481.64
71 (91.1)
4.1481.77
71 (91.1)
MPH 6.783.5 5.181.7 4.581.9 4.382
LD 7.283.6 5.481.9 4.881.9 4.882.4
MPH + LD 6.482.6 4.180.9 3.781.3 3.481.3
Placebo 6.583.5 5.782.1 5.782.2 5.782.1
Group effect
F
p
0.199
0.896a
11.944
0.008b
3.683
0.016a
4.694
0.005b
Time effect
F
p
32.927
0.000
Group ! time effect
F
p
1.564
0.205
Post hoc comparison (MPH + LD < placebo)
p n.s. n.s. 0.018 0.006
Post hoc comparison of time points, t value
p 5.447c
5.537d
5.714e
0.000
0.000
0.000
2.850f
3.414g
1.580h
0.006
0.01
0.118
F igures are means 8 SD, unless otherwise indicated. Higher scores of GDS indicate worse function. n.s. = Not significant.
a p value of F test. b p value of 2 test. c Baseline vs. 15-day follow-up. d Baseline vs. 90-day follow-up. e Baseline vs. 180-day follow-
up. f 15-day vs. 90-day follow-up. g 15-day vs. 180-day follow-up. h 90-day vs. 180-day follow-up.
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make MPH an attractive alternative for the treatment of 
mood disorder in stroke patients  [34] . The therapeutic ef-
fects of MPH in the treatment of depression has been at-
tributed to its ability to improve mood, motivation and 
other cognitive functions including attention, working 
memory, and executive functions  [36] .
 Cognitive impairment is frequently associated with 
mood disorder in stroke patients, and the nature of the 
relationship between cognitive impairment and PSD re-
mains complex  [37] . In our study, we found no group dif-
ferences regarding cognition. However, the depressed 
 patients showed significantly greater improvements in 
cognitive function than the non-depressed individuals, 
which is in line with earlier findings where stroke pa-
tients have partially reversible cognitive dysfunction 
when their depressive disorder is successfully treated 
 [28] .
 We suggest that the lack of effect of MPH and/or LD on 
cognitive impairment might in part be related to the cog-
nitive assessment scale, which is not sensitive enough to 
catch minor changes. The MMSE as a standardized scale 
for the assessment of cognitive function evaluates five ar-
eas of cognitive functions. Although it is sensitive to at-
tention, recall, and language, it does not encompass all the 
cognitive deficits and is particularly weak in its ability to 
measure executive functions such as abstract thinking, 
judgment, problem solving, and perception  [38] .
 Neuropsychiatric sequelae after stroke seem to have a 
natural recovery course  [39] . The main theories recog-
nized to date state that most spontaneous recovery tends 
to arise within the first 3 months after stroke onset, and 
that cognitive impairments are more likely than motor 
deficits to show spontaneous achievements beyond those 
months. In our study, the strongest improvement of time 
effect in mood and cognitive functions occurred during 
the first 15 days of treatment. However, it is difficult to 
differentiate spontaneous from therapy-induced recov-
ery  [40] .
 Some study limitations exist. The primary limitation 
was the small sample size. We experienced similar diffi-
culties with patient recruitment as other studies due to a 
wide range of exclusion criteria. Although we chose wide 
inclusion criteria for stroke patients, more than 90% of 
the screened stroke patients did not meet the initial eligi-
bility criteria and were therefore excluded. However, 78 
patients of the 100 finally recruited patients completed 
the study. Although MPH and LD affected mood func-
tion significantly in our study, the effect size was not con-
sistently large. Larger and perhaps more consistent effects 
may be achieved with a higher dose of active drugs, with 
a more frequent and longer duration of treatments, with 
recruitment of patients earlier after stroke onset, and by 
identifying patients prone to respond to treatment. Stud-
ies that showed a significant effect of MPH and LD on 
mood and cognition recruited patients early after stroke 
onset, i.e. 3–40 days after the stroke, while in our study 
patients entered the trial on average 65.6 days after stroke 
onset  [11, 41, 42] . Nevertheless, the studies up to now are 
limited in a number of ways, and definitive conclusions 
cannot yet be drawn. The sample sizes were small, follow-
up periods were either missing or relatively short, a wide 
range of drug doses was used, and the results were un-
convincing or discrepant. Thus, further evaluation with 
large randomized, placebo-controlled, double-blind tri-
als is needed to more clearly assess the role of MPH and 
LD in neuropsychiatric sequelae after stroke.
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